SL-80. Analgesics

ASINEX
Signature Libraries

Several promising target families (i.e. GPCR, ion channels) have been investigated in order to address unmet need in the treatment of acute and chronic pain [1]. One possible strategy to achieve the desired pharmacological effect without causing negative side effects and addiction is targeting peripheral μ-opioid receptors. 3-substituted piperidine molecules (e.g. NFEPP) were shown to bind specifically to peripheral μ-opioid receptors in acidified peripheral tissues [2]. Another strategy to reduce the negative opioid side effect is focused on optimizing a ligand's structure and properties by using opioid receptors' crystal information [3].

Asinex has created several novel 3-substituted 2-benzylpiperidine derivatives that represent an interesting chemotype for studying opiod receptor signaling.



LAS 73700634



LAS 52207105



LAS 51749203

Signature Library 80

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 μmol; 1 μmolDMSO solutions	SL#80_Analgesic_for_CNS-1.sdf

References:

1. .*Nature Reviews Drug Discovery,* v.16, pp. 545–564 (2017). doi: 10.1038/nrd.2017.87
2. *Science,* 2017 Mar 3; 355(6328):966-969. doi: 10.1126/science.aai8636.
3. *Nature,* 2016 Sep 8; 537(7619):185-190. doi: 10.1038/nature19112.

Contact us:

USA:	+1 336 721 1617	mparisi@asinex.com
Japan:	+81-80-3401-9097	sota@asinex.com
Europe/Global:		lsadovenko@asinex.com